ty-1091
RET-altered Papillary Thyroid Cancer
TYK Medicines, IncPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the RET-altered Papillary Thyroid Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
Cobimetinib Cancer Research UK | Phase 2/3 | B |
gsk1120212 Cancer Research UK | Phase 2/3 | B |
Dabrafenib Cancer Research UK | Phase 2/3 | B |
VEMURAFENIB Cancer Research UK | Phase 2/3 | CCC |
View all 31 →
Same molecule, other indications
ty-1091 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →